Background/Aims We aim to evaluate the effects of auranofin, a known antioxidant, on hepatic steatosis, inflammation, and fibrosis, contributing to non-alcoholic steatohepatitis (NASH) development in vivo and in vitro.
Methods Transcriptome analysis of LX-2 cells was that expression patterns of genes changed by auranofin, and their related pathways were estimated. We used the gene set enrichment analysis (GSEA) program to determine the pathway involved in overall genetic change. In vitro, LX-2 and HepG2 cells were treated with transforming growth factor (TGF)-β1 and palmitic acid (PA), respectively, and the antifibrotic and antiadipogenic effect function of auranofin was evaluated.
Results Transcriptome analysis revealed that auranofin decreased the expression of 15 genes, including thrombospondin 1, endothelin 1 (ET-1), fibronectin 1, and LOX. The molecular functions of these genes are involved in collagen binding. GSEA of the overall gene expression pattern revealed that many genes increased in the reactive oxygen species pathway and decreased in the inflammatory response. Auranofin decreased nuclear factor kappa B (NF-κB) and IκBα in TGF-β1-induced LX-2 cells, thereby reducing ET-1 and fibrosis. Furthermore, increased pNRF2 in PA-induced HepG2 cells led to increased antioxidant marker expression and decreased lipid accumulation. In the bile duct ligation model mice, auranofin reduced the fibrosis area and increased the survival rate. Auranofin reduced liver fibrosis and lipid accumulation in NASH model mice fed on a Western diet.
Conclusions Auranofin inhibits lipogenesis and fibrosis formation and is a proposed candidate for NASH treatment.
Citations
Citations to this article as recorded by
Reactive oxygen species promotion drives auranofin’s antiviral activity against hepatitis E virus Kateland Tiller, S. Tyler Williams, Bo Wang, Debin Tian, Xiang-Jin Meng, James Weger-Lucarelli, Guangxiang George Luo Journal of Virology.2026;[Epub] CrossRef
FAM83A acts as an amplifier for lipogenic signaling to facilitate the pathogenesis of metabolic dysfunction-associated steatohepatitis Yang Zhou, Yuhang Dai, Mengyao Qin, Yecheng Li, Lunan Shi, Hao Chen, Hui Fan, Yunli Yu, Le Guo, Jing Xiong Metabolism.2026; 175: 156462. CrossRef
Aurocyanide, an active metabolite of auranofin, exerts cytoprotective effects via ROS-mediated Nrf2 activation in HepG2 cells Undarmaa Otgontenger, Seokwon Yang, Eun Kyung Kim, Young-Mi Kim Toxicology and Applied Pharmacology.2026; 506: 117656. CrossRef
Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease Alfredo Smiriglia, Nicla Lorito, Marina Bacci, Angela Subbiani, Francesca Bonechi, Giuseppina Comito, Marta Anna Kowalik, Andrea Perra, Andrea Morandi Cell Death & Disease.2025;[Epub] CrossRef
The protective role of kakkalide in sepsis-induced intestinal barrier dysfunction via inhibition of NF-κB pathway activation Tongrong Xu, Jiahui Han, Nan Wang, Zhirong Huan, Hao Yao, Xin Ge Journal of Clinical Biochemistry and Nutrition.2025; 76(2): 139. CrossRef
Fucoidan ameliorates lipid accumulation, oxidative stress, and NF-κB-mediated inflammation by regulating the PI3K/AKT/Nrf2 signaling pathway in a free fatty acid-induced NAFLD spheroid model Xueru Chu, Xuan Wang, Keqing Feng, Yanzhen Bi, Yongning Xin, Shousheng Liu Lipids in Health and Disease.2025;[Epub] CrossRef
Sanye tablet regulates gut microbiota and bile acid metabolism to attenuate hepatic steatosis Yulin Qi, Siqi Du, Wenwen Li, Xianzhe Qiu, Fengjie Zhou, Liding Bai, Boli Zhang, Zhuoxin Mi, Weiqiang Qian, Lin Li, Xin Zhao, Yuhong Li Journal of Ethnopharmacology.2025; 345: 119514. CrossRef
Acteoside inhibits hepatic lipid accumulation and oxidative stress in type 2 diabetic mice via the Nrf2/HO-1 Pathway Dan-Dan Hao, Lei Zhang, Si-Lin Liu, Zhi-Juan Sun, Ri-Gu-Leng Si, Feng-Ning Zhang, Li-Xin Yang, Xiao-Li Jia, Tian-Zhu Li, Lin Ai, Chun-Ying Bai, Kai Gu, Cong-Ying Zhang Journal of Toxicology and Environmental Health, Part A.2025; 88(15): 616. CrossRef
Protective effects of Scutellaria barbata against hepatocyte apoptosis during hepatic fibrosis progression Feng Li, Bi Wang, Xianxian Fu, Jinqiang Liang, Xi Xiao, Xiaobin Wei Cytotechnology.2025;[Epub] CrossRef
The rheumatoid arthritis drug Auranofin targets peroxiredoxin 1 and peroxiredoxin 2 to trigger ROS-endoplasmic reticulum stress axis-mediated cell death and cytoprotective autophagy Wenyue Yang, Zhou Zhu, Chaohua Zhou, Junhui Chen, Jinhuan Ou, Haibo Tong, Ashok Iyaswamy, Peng Chen, Xu Wei, Chuanbin Yang, Wei Xiao, Jigang Wang, Wei Zhang Free Radical Biology and Medicine.2025; 233: 1. CrossRef
ELANE enhances KEAP1 protein stability and reduces NRF2-mediated ferroptosis inhibition in metabolic dysfunction-associated fatty liver disease Qingqing Yang, Xuan Shen, Yan Luo, Rongqing Li, Xiangrui Meng, Ping Xu, Xuan Liu, Dongxue Bian, Jianhua Wang, Junping Shi, Jin Chen Cell Death & Disease.2025;[Epub] CrossRef
Searching for New Gold(I)-Based Complexes as Anticancer and/or Antiviral Agents Paola Checconi, Annaluisa Mariconda, Alessia Catalano, Jessica Ceramella, Michele Pellegrino, Stefano Aquaro, Maria Stefania Sinicropi, Pasquale Longo Molecules.2025; 30(8): 1726. CrossRef
Weissella viridescens Attenuates Hepatic Injury, Oxidative Stress, and Inflammation in a Rat Model of High-Fat Diet-Induced MASLD Shuwei Zhang, Ruiqing Zhao, Ruoshi Wang, Yao Lu, Mingchao Xu, Xiaoying Lin, Ruiting Lan, Suping Zhang, Huijing Tang, Qianhua Fan, Jing Yang, Liyun Liu, Jianguo Xu Nutrients.2025; 17(9): 1585. CrossRef
From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood Siham Accacha, Julia Barillas-Cerritos, Ankita Srivastava, Frances Ross, Wendy Drewes, Shelly Gulkarov, Joshua De Leon, Allison B. Reiss Metabolites.2025; 15(5): 287. CrossRef
Combination Therapy of Half-Dose Resmetirom and Metformin Attenuates Metabolic Dysfunction-Associated Steatohepatitis Through Improving Cholesterol Metabolism and Inflammation Wenxiu Liu, Fan Yao, Jinghan Wang, Nan Shao, Xinxin Cao, Zhengqi Dong, Bin Zhang, Xiaobo Sun Biomedicines.2025; 13(6): 1315. CrossRef
TGF-β inhibitors: the future for prevention and treatment of liver fibrosis? Weili Wang, Yilin Gao, Yizhen Chen, Meng Cheng, Yonghao Sang, Liuting Wei, Rong Dai, Yiping Wang, Lei Zhang Frontiers in Immunology.2025;[Epub] CrossRef
Integrative transcriptomic profiling of NK cells and monocytes: Advancing diagnostic and therapeutic strategies for COVID-19 Salma Loukman, Reda Ben Mrid, Najat Bouchmaa, Hicham Hboub, Rachid El Fatimy, Rachid Benhida Computational and Structural Biotechnology Reports.2025; 2: 100059. CrossRef
Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin Jingyi Ma, Wendy van de Sande, Bernhard Biersack International Journal of Molecular Sciences.2025; 26(16): 7909. CrossRef
A novel phosphodiesterase 5 inhibitor, CPD1, alleviates liver fibrosis by modulating the Akt/NF-κB pathway to inhibit activated hepatic stellate cells Wenbin Feng, Jianqin Yang, Jiaxiu Lei, Limei Li, Changfeng Shan, Shenjie Chen, Zongmeng Zhang, Zhenggang Zhao, Sujin Zhou, Allan Zijian Zhao, Yunping Mu, Fanghong Li Biochemical Pharmacology.2025; 242: 117388. CrossRef
Effects of Tributyrin on Antioxidant Capacity, Immune Function, and Liver Macrophage Polarization in Weaned Piglets Under LPS Challenge Meng Yuan, Shuai Ning, Dongming Yu, Fei Long, Weite Li, Jun Qi, Yaxu Liang, Changming Hong, Yingzhang Tang, Chunxue Liu, Gaiqin Wang, Bencheng Wu, Xiang Zhong Animals.2025; 15(19): 2842. CrossRef
The Involvement of Endothelin-1 in Sepsis and Organ Dysfunction—A Novel Biomarker in Patient Assessment Cristian Sorin Prepeliuc, Maria Antoanela Pasăre, Maria Gabriela Grigoriu, Ionela Larisa Miftode, Radu Ștefan Miftode, Andrei Vâță, Irina Iuliana Costache-Enache, Egidia Gabriela Miftode Biomedicines.2025; 13(10): 2480. CrossRef
Huazhi Rougan Granule Alleviates Liver and Intestinal Damage in Non-Alcoholic Fatty Liver Disease by Regulating miR-122 Expression and TLR4/MyD88/NF-κB Pathway Activation Ping Xie, Xiaowei Jin, Chan Li, Kun Lv, Ming Deng Combinatorial Chemistry & High Throughput Screening.2025; 28(17): 3002. CrossRef
Activation of AMPK pathway by low‑dose donafenib and atorvastatin combination improves high‑fat diet‑induced metabolic dysfunction‑associated steatotic liver disease Yaowei Bai, Kequan Chen, Jiacheng Liu, Yingliang Wang, Chaoyang Wang, Shuguang Ju, Chen Zhou, Wei Yao, Bin Xiong, Chuansheng Zheng Molecular Medicine Reports.2024;[Epub] CrossRef
Network pharmacology and transcriptomic profiling elucidate the therapeutic effects of Ranunculus ternatus Thunb on liver fibrosis via MK3-NF-κB inhibition Lu Han, Guoyuan Lin, Jianchao Li, Qingxiu Zhang, Tao Ran, Tao Huang, Ruihan Hu, Shu Feng, Gaoliang Zou, Shaojie Chen, Xueke Zhao Aging.2024;[Epub] CrossRef
Increasing prevalence of cirrhosis among insured adults in the United States, 2012–2018 Daniela P. Ladner, Michael Gmeiner, Bima J. Hasjim, Nikhilesh Mazumder, Raymond Kang, Emily Parker, John Stephen, Praneet Polineni, Anna Chorniy, Lihui Zhao, Lisa B. VanWagner, Ronald T. Ackermann, Charles F. Manski, Sona Frankova PLOS ONE.2024; 19(2): e0298887. CrossRef
Oxysophoridine inhibits oxidative stress and inflammation in hepatic fibrosis via regulating Nrf2 and NF-κB pathways Jian-Yu Chen, Ying-Jie Yang, Xiong-Yu Meng, Ru-Hui Lin, Xiao-Yun Tian, Ying Zhang, Wen-Fang Lai, Chunxue Yang, Xue-Qin Ma, Ming-Qing Huang Phytomedicine.2024; 132: 155585. CrossRef
RETRACTED: NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies Aryan Rezaee, Parham Rahmanian, Amirreza Nemati, Farima Sohrabifard, Fatemeh Karimi, Ali Elahinia, Ali Ranjbarpazuki, Rozhin Lashkarbolouki, Sadaf Dezfulian, Mohammad Arad Zandieh, Shokooh Salimimoghadam, Noushin Nabavi, Mohsen Rashidi, Afshin Taheriazam, Heliyon.2024; 10(9): e29871. CrossRef
Tricetin protects against liver fibrosis through promoting autophagy and Nrf2 signaling in hepatic stellate cells Wanzhi Li, Ruyue Lv, Tangbin Zou, Ming Chen Life Sciences.2024; 351: 122798. CrossRef
Exploring the molecular mechanisms and shared potential drugs between rheumatoid arthritis and arthrofibrosis based on large language model and synovial microenvironment analysis Zhaoquan Wei, Xi Chen, Youshi Sun, Yifei Zhang, Ruifang Dong, Xiaojing Wang, Shuangtao Chen Scientific Reports.2024;[Epub] CrossRef
Evaluating the therapeutic potential of genetically engineered probiotic Zbiotics (ZB183) for non-alcoholic steatohepatitis (NASH) management via modulation of the cGAS-STING pathway Maha Saad, Walaa Ibrahim, Amany Helmy Hasanin, Aya Magdy Elyamany, Marwa Matboli RSC Medicinal Chemistry.2024; 15(11): 3817. CrossRef
Cellular fibronectin-targeted fluorescent aptamer probes for early detection and staging of liver fibrosis Mengjun Ge, Haitao Zou, Jiahao Chen, Qinyao Zhang, Chang Li, Jiaxing Yang, Jiumei Wu, Xing Xie, Jun Liu, Lei Lei, Shaoliang Peng, Hemin Nie Acta Biomaterialia.2024; 190: 579. CrossRef
Induced collagen type‐I secretion by hepatocytes of the melanoma liver metastasis is associated with a reduction in tumour‐infiltrating lymphocytes Shodai Mizuno, Matias A. Bustos, Yoshinori Hayashi, Kodai Abe, Satoru Furuhashi, Yalda Naeini, Xiaowei Xu, Anton J Bilchik, Dave S. B. Hoon Clinical and Translational Medicine.2024;[Epub] CrossRef
Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways” Yuanbin Liu, Mingkai Chen Clinical and Molecular Hepatology.2023; 29(1): 163. CrossRef
Oleoylethanolamide alleviates hyperlipidaemia-mediated vascular calcification via attenuating mitochondrial DNA stress triggered autophagy-dependent ferroptosis by activating PPARα Zhengdong Chen, Xuejiao Sun, Xiaoxue Li, Naifeng Liu Biochemical Pharmacology.2023; 208: 115379. CrossRef
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response Silvia Sookoian, Carlos J. Pirola Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef
CRISPR/Cas9-Based Screening of FDA-Approved Drugs for NRF2 Activation: A Novel Approach to Discover Therapeutics for Non-Alcoholic Fatty Liver Disease James Li, Sandra Arest, Bartlomiej Olszowy, John Gordon, Carlos A. Barrero, Oscar Perez-Leal Antioxidants.2023; 12(7): 1363. CrossRef
Perfluorodecanoic acid promotes high-fat diet-triggered adiposity and hepatic lipid accumulation by modulating the NLRP3/caspase-1 pathway in male C57BL/6J mice Taotao Wang, Hong Xu, Yu Guo, Yuanxin Guo, Huanan Guan, Dongxu Wang Food and Chemical Toxicology.2023; 178: 113943. CrossRef
Higher pNRF2, SOCS3, IRF3, and RIG1 Tissue Protein Expression in NASH Patients versus NAFL Patients: pNRF2 Expression Is Concomitantly Associated with Elevated Fasting Glucose Levels Suzan Schwertheim, Malek Alhardan, Paul P. Manka, Jan-Peter Sowa, Ali Canbay, Hartmut H.-J. Schmidt, Hideo A. Baba, Julia Kälsch Journal of Personalized Medicine.2023; 13(7): 1152. CrossRef
Molecular mechanisms and clinical implications of the gold drug auranofin Shuying Shen, Jie Shen, Zhong Luo, Fudi Wang, Junxia Min Coordination Chemistry Reviews.2023; 493: 215323. CrossRef
Impaired NRF2 Inhibits Recovery from Ischemic Reperfusion Injury in the Aging Kidney Min Jee Jo, Ji Eun Kim, So Yon Bae, Eunjung Cho, Shin Young Ahn, Young Joo Kwon, Gang-Jee Ko Antioxidants.2023; 12(7): 1440. CrossRef
Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis Kuanhong Luo, Yang Chen, Shuzheng Fang, Siqi Wang, Zhixin Wu, Huiqing Li Frontiers in Endocrinology.2023;[Epub] CrossRef
Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE Layla A. Al-Kharashi, Naif O. Al-Harbi, Sheikh F. Ahmad, Sabry M. Attia, Mohammad M. Algahtani, Khalid E. Ibrahim, Saleh A. Bakheet, Mohammed M. Alanazi, Saleh A. Alqarni, Sary Alsanea, Ahmed Nadeem Biomedicines.2023; 11(9): 2502. CrossRef
Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait Carlos J. Pirola, Silvia Sookoian Clinical and Molecular Hepatology.2022; 28(4): 806. CrossRef
Background/Aims We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD).
Methods An exploration study (study I) was performed using three different NAFLD models (basket study design; high-fat diet [HFD], methionine choline-deficient diet [MCD], and high-cholesterol Western diet [WD] models). RNA transcriptome analysis was performed on pre-studied liver tissues to identify biomarkers that could predict the response to DPP-4 inhibitors. In the validation study (study II), the HFD-induced NAFLD model was divided into high and low hepatic insulin-like growth factor binding protein 1 (Igfbp-1) groups based on the pre-study liver biopsy.
Results DPP-4 inhibitor attenuated the NAFLD activity score and fibrosis stage in the HFD model but not in the WD and MCD models. The overall response rate was 19% across the modified basket NAFLD trial and 42%, 25%, and 0% in the HFD, WD, and MCD models. Hepatic Igfbp-1 expression was higher in the responder group than in the non-responder group in pre-study biopsy samples. In contrast, hepatic Igfbp-1 expression was lower in the responder group than in the non-responder group in the end-study biopsy samples. DPP-4 inhibitor response rates were 83% and 17% in the baseline hepatic high Igfbp-1 and low Igfbp-1 groups, respectively. Hepatic messenger RNA Igfbp-1 expression was positively correlated with serum IGFBP-1 levels.
Conclusions The DPP-4 inhibitor response was higher in the HFD phenotype and pre-treatment levels of hepatic or serum IGFBP-1 were high.
Citations
Citations to this article as recorded by
Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun Diagnostics.2025; 15(3): 342. CrossRef
New clinical trial design in precision medicine: discovery, development and direction Xiao-Peng Duan, Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Zhan Wang, Yuan-Sheng Zang Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Eun Jeoung Lee, Seung Min Lee, Ju Hee Oh, Hye Young Kim, Waqar Khalid Saeed, Hyun Sung Kim, Dae Won Jun Nutrients.2024; 16(7): 920. CrossRef
Discovery of Nine Dipeptidyl Peptidase-4 Inhibitors from Coptis chinensis Using Virtual Screening, Bioactivity Evaluation, and Binding Studies Zixi Zhao, Ruonan Ma, Yuqing Ma, Liqiang Zhao, Lele Wang, Yuzhen Fang, Yuxin Zhang, Xia Wu, Xing Wang Molecules.2024; 29(10): 2304. CrossRef
DPP-IV as a potential candidate in anti-obesity and obesity-related diseases treatment Xin Guo, Huolun Feng, Liyang Cai, Jiabin Zheng, Yong Li Biomedicine & Pharmacotherapy.2024; 180: 117464. CrossRef
From NAFLD to HCC: Advances in noninvasive diagnosis Qinchen Xu, Maoxiao Feng, Yidan Ren, Xiaoyan Liu, Huiru Gao, Zigan Li, Xin Su, Qin Wang, Yunshan Wang Biomedicine & Pharmacotherapy.2023; 165: 115028. CrossRef
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review Rong Xu, Difei Lian, Yan Xie, Zhilei Chen, Yan Wang, Lin Mu, Yuan Wang, Baoyu Zhang Frontiers in Bioscience-Landmark.2023;[Epub] CrossRef
Lessons on Drug Development: A Literature Review of Challenges Faced in Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Trials Joel Yeh Siang Chen, Damien Chua, Carissa Odelia Lim, Wan Xi Ho, Nguan Soon Tan International Journal of Molecular Sciences.2022; 24(1): 158. CrossRef
First
Prev
